All In Biotech

Drug Trial Radar · NCT07247227

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

Sugemalimab Plus Platinum-based Chemotherapy as First-line Therapy for Patients With Locally Advanced and Metastatic Non-small Cell Lung Cancer (NSCLC) in a Real-world Setting: a Single-arm, Multi-center Study

Last checked: Nov 20, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 10, 2023

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Peking Union Medical CollegeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This single-arm, multi-center study is to evaluate Sugemalimab plus platinum-based chemotherapy as first-line therapy for patients with locally advanced and metastatic NSCLC in a real-world setting.

Conditions

  • NSCLC

Interventions

  • Sugemalimab and ChemotherapyDrug

    Sugemalimab 1200mg plus 4-6 cycles of platinum-based chemotherapy as first-line therapy, followed by Sugemalimab 1200mg to 35 cycles, or until disease progression, or ICF withdrawn by participants, or death or unacceptable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. rw-PFSTime frame: From enrollment to the end of treatment at 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • cancer hospital, Chinese Academy of medical sciences and Peking union medical college

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.